Following on from information provided to NICE by the company in July 2018, the appraisal of Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 864

Email enquiries

Stakeholders

Companies sponsors Orphan Europe
Others Department of Health
  NHS England
  NHS Cumbria CCG
  NHS Redditch and Bromsgrove CCG
  Welsh Government
Patient carer groups Leukaemia CARE
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Shire Pharmaceuticals (pegylated asparaginase)
  Jazz Pharmaceuticals (Erwinia-derived asparaginase)
  Medac GmbH (E.coli asparaginase) (no confidentiality agreement signed not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in July 2018, the appraisal of Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
27 June 2018 - 25 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
06 July 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of erythrocyte encapsulated asparaginase within its marketing authorisation for treating acute lymphoblastic leukaemia. For information, the company have now advised that they will not be pursuing a marketing authorisation application for erythrocyte encapsulated asparaginase from the European Medicines Authority for this indication at this time. Therefore, NICE have cancelled the consultation for this topic and have decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and provide an update as and when the situation changes.
06 July 2018 Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of erythrocyte encapsulated asparaginase within its marketing authorisation for treating acute lymphoblastic leukaemia. For information, the company have now advised that they will not be pursuing a marketing authorisation application for erythrocyte encapsulated asparaginase from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to cancel the consultation for this topic at this time and suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and provide an update as and when the situation changes.
05 July 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of erythrocyte encapsulated asparaginase within its marketing authorisation for treating acute lymphoblastic leukaemia. For information, the company have now advised that they will not be pursuing a marketing authorisation application for erythrocyte encapsulated asparaginase from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. We have therefore cancelled the consultation for this topic at this stage. As the appraisal has been referred, NICE will continue to monitor any developments and provide an update as and when the situation changes.
28 October 2016 Suspended. the company that markets the technology has informed NICE of a delay to regulatory proceedings, therefore they will not provide an evidence submission for this appraisal at this time. NICE will suspend this appraisal and provide further updates when they are available.
08 August 2016 Invitation to participate
01 April 2016 Draft scope documents
15 March 2016 Referral
15 March 2016 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual